Phase
Alumni community member
Acrivon Therapeutics / Acrivon AB
Acrivon Therapeutics specializes in accelerated drug development in oncology, using a unique, predictive phospho-proteomic approach. Their patented technology platform identifies drug-tailored biomarker signatures for patient responder identification, which increases efficacy, reduces toxicity and precisely matches the therapy with patients who will benefit.
Kristina Masson, Head of Acrivon AB and Co-Founder of the Boston-based Headquarters. Between experts in the US, Sweden and Denmark, we are building our dream team to tackle one of the biggest challenges in the oncology industry. The name Acrivon is inspired by the Greek word for accurate.
Did you know?
Acrivon’s method is applicable across drug modalities and diseases!
Non-invasive cardiac pressure monitoring device
Accelerated drug development in oncology
Unique stem cell therapeutics
3D cell culture systems
Rapid Diagnostics for Multi-pathogen detection
Individualised information of the intestinal flora
Imaging solutions for life sciences
Novel probiotics for therapeutic effect
Treatments based on nature’s own defenses
Pest control solutions for bed bugs
Neonatal Lung Analyzer
Prebiotics for irritable bowel syndrome
Nanotechnology based infection control
Excellence in designing & executing drug discovery
Models for autoimmune & inflammatory conditions
Ultrasensitive cancer diagnostics & monitoring
Structural biology & drug discovery services
Male-Factor Infertility Diagnostics
Customized in vitro and in vivo services
Stroke detection device
Wound treatment gel
Regenerative medicine & cancer
